Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

BMI and waist measures not effective in predicting CVD risk

Body measurements such as BMI, waist circumference and waist-to-hip ratio are not useful in calculating cardiovascular disease (CVD) risk when details of other risk factors are available, a Cambrige University study has found.

In an analysis of 58 studies with more than 221,000 participants, researchers found all three measurements did not improve CVD risk prediction, either when used alone or in combination, when data on other risk factors (such as smoking status, diabetes, systolic blood pressure and cholesterol) were available.

Ultimately, "simple adiposity measures provide little or no additional information on cardiovascular risk," the authors concluded.

However, the authors warned that the study, published in The Lancet, did not mean adiposity was not a major modifiable cause of CVD, as it was still a risk factor for developing high blood pressure, high cholesterol and diabetes.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD013856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel